Relmada named Bipin Dalmia as chief business officer, leading corporate strategy, commercial planning and business development, and he will report to CEO Sergio Traversa.
Dalmia brings nearly three decades in biopharma leadership, spanning NMIBC, corporate strategy and business development.
The appointment aligns with the NDV-01 program as Relmada moves toward late-stage development for its sustained-release intravesical NMIBC therapy.
RLMD•
